Press release
HER2+ Gastric Cancer Pipeline: 20+ Players, Clinical & Non-Clinical Studies, Emerging Therapies, and Treatment Landscape | Jiangsu HengRui Medicine, Pieris Pharmaceuticals, BioInvent International
HER2+ Gastric Cancer Companies are AstraZeneca, Shanghai JMT-Bio, Acepodia Biotech, Klus Pharma, Carisma Therapeutics, Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio, Shanghai Miracogen, Bavarian Nordic
With HER2-positive gastric cancer contributing significantly to global cancer morbidity and mortality, there remains a critical need for more effective and targeted therapies. Addressing this unmet need, DelveInsight's "HER2+ Gastric Cancer Pipeline Insight 2024" report offers a detailed analysis of the dynamic therapeutic landscape, spotlighting 20+ key pharmaceutical and biotech players involved in the development of 20+ innovative treatment candidates.
The report provides a comprehensive assessment of clinical and non-clinical studies, emerging drug profiles, trial phase progression, mechanism of action, and recent strategic developments. It also evaluates the current treatment algorithm, identifies unmet needs, and explores future growth opportunities in the HER2+ Gastric Cancer Therapeutics Market.
Request for a HER2+ gastric cancer pipeline insights 2024 report @ https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the HER2+ Gastric Cancer Pipeline Report
*
DelveInsight's HER2+ Gastric Cancer pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for HER2+ Gastric Cancer treatment.
*
In July 2024, Merck & Co. announced that the Phase III KEYNOTE-811 trial achieved its dual primary endpoint of overall survival. The study evaluated Keytruda in combination with trastuzumab and chemotherapy containing fluoropyrimidine and platinum for the first-line treatment of patients with HER2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
*
In April 2024, ENHERTU (fam-trastuzumab deruxtecan-nxki) received approval in the US as the first tumor-agnostic HER2-targeted therapy for patients with metastatic HER2-positive solid tumors who have undergone prior treatment.
*
Key companies in the HER2+ Gastric Cancer treatment landscape include Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo, AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc, Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc., Bavarian Nordic, and others.
*
Promising HER2+ Gastric Cancer pipeline therapies in various stages of development include SHR-A1811, Cinrebafusp alfa, BI-1607, and others.
HER2+ Gastric Cancer Overview:
Gastric cancer ranks as the sixth most common cancer globally and the third leading cause of cancer-related deaths. Early-stage gastric cancer is often asymptomatic, with most symptoms appearing only in advanced stages. Common late-stage symptoms include unexplained weight loss, stomach pain, loss of appetite, difficulty swallowing, fatigue, nausea, vomiting, heartburn, and indigestion. Gastric cancer develops due to genetic mutations in stomach cells, causing abnormal cell growth and tumor formation.
A subset of gastric cancers is HER2-positive, characterized by overexpression of the HER2 protein, which promotes tumor growth. HER2, a member of the EGFR family, is encoded by a gene located on chromosome 17 (17q21). HER2-positive cancers can benefit from targeted therapies that inhibit the HER2 protein, though only a minority of patients achieve a cure through surgical resection, with many experiencing recurrence.
The HER2 protein, also known as ErbB2/Neu, is a 185 kDa transmembrane glycoprotein with three key components: an extracellular ligand-binding domain, a transmembrane domain, and an intracellular tyrosine kinase domain. Advances in HER2-targeted treatments provide a promising approach for managing HER2-positive gastric cancers.
Request for detailed information on HER2+ gastric cancer pipeline insights report @ https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
HER2+ Gastric Cancer Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the HER2+ Gastric Cancer Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2+ Gastric Cancer treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the HER2+ Gastric Cancer market.
HER2 Positive Gastric Cancer Emerging Drugs
*
SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
*
Cinrebafusp alfa: Pieris Pharmaceuticals
*
BI-1607: BioInvent International
HER2+ Gastric Cancer Companies
Approximately 20 or more key companies are actively developing therapies for HER2-positive gastric cancer. Among these, Jiangsu HengRui Medicine Co., Ltd. has drug candidates in the most advanced stage of development, specifically Phase III clinical trials.
DelveInsight's report covers around 22+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
HER2+ Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
HER2+ Gastric Cancer Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging HER2+ Gastric Cancer Therapies and Key Companies: HER2+ Gastric Cancer Clinical Trials and advancements [https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
HER2+ Gastric Cancer Pipeline Therapeutic Assessment
- HER2+ Gastric Cancer Assessment by Product Type
- HER2+ Gastric Cancer By Stage
- HER2+ Gastric Cancer Assessment by Route of Administration
- HER2+ Gastric Cancer Assessment by Molecule Type
Download HER2+ Gastric Cancer Sample report to know in detail about the HER2+ Gastric Cancer treatment market @ HER2+ Gastric Cancer Therapeutic Assessment [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. HER2+ Gastric Cancer Current Treatment Patterns
4. HER2+ Gastric Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. HER2+ Gastric Cancer Late-Stage Products (Phase-III)
7. HER2+ Gastric Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. HER2+ Gastric Cancer Discontinued Products
13. HER2+ Gastric Cancer Product Profiles
14. HER2+ Gastric Cancer Key Companies
15. HER2+ Gastric Cancer Key Products
16. Dormant and Discontinued Products
17. HER2+ Gastric Cancer Unmet Needs
18. HER2+ Gastric Cancer Future Perspectives
19. HER2+ Gastric Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the HER2+ Gastric Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=her2-gastric-cancer-pipeline-20-players-clinical-nonclinical-studies-emerging-therapies-and-treatment-landscape-jiangsu-hengrui-medicine-pieris-pharmaceuticals-bioinvent-international]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HER2+ Gastric Cancer Pipeline: 20+ Players, Clinical & Non-Clinical Studies, Emerging Therapies, and Treatment Landscape | Jiangsu HengRui Medicine, Pieris Pharmaceuticals, BioInvent International here
News-ID: 4078700 • Views: …
More Releases from ABNewswire
Yasam Ayavefe and the Future of Technology Driven Learning
Image: https://cp.adsy.com/upload/images/2025/12/09/image_69380ef7da77b.png
The rapid evolution of artificial intelligence, automation, cybersecurity, and data driven systems has transformed how individuals and organizations approach education. In 2025, the global technology landscape is advancing at an unprecedented pace, creating an urgent need for adaptive, accessible, and forward looking learning models. Within this momentum, Yasam Ayavefe and the initiatives surrounding Yasam Ayavefe Academy stand out for promoting a new vision of technology focused education that prepares…
Bestselling Author and Leadership Coach Thanh Nguyen Releases Transformational N …
Loving Heart Publishing proudly announces the release of Unshrink Yourself: 12 Mini-Shifts to Ditch Self-Doubt and Own Your Life (ISBN: 9798990893047), the empowering new self-help book by bestselling author, professor, and leadership coach Thanh Nguyen.
Stop Shrinking. Start Owning Your Life.
With warmth, wisdom, and raw honesty, Nguyen delivers a no-nonsense, heart-driven guide for anyone ready to silence their inner critic and start living boldly. Drawing on her personal journey from voiceless…
Yasam Ayavefe and the Acceleration of AI Focused Learning in 2025
Image: https://cp.adsy.com/upload/images/2025/12/09/image_69380cdb12711.png
As artificial intelligence continues reshaping industries across the globe, the demand for accessible and future ready education has become stronger than ever. The rapid adoption of automation, machine learning, and data driven decision systems has pushed both individuals and institutions to rethink how learning is delivered. Within this evolving landscape, Yasam Ayavefe has emerged as a compelling figure, inspiring new approaches to skill development through initiatives such as Yasam…
Real Illusions - 2025 London Contemporary Art Review Exhibition
Image: https://www.abnewswire.com/upload/2025/12/356ce40b902e11f77e0070164968b676.jpg
The list of award-winning artists for the British International Art Competition "Real Illusions - 2025 London Contemporary Art Review Exhibition," organized by Gallery NAT London [https://www.gallerynat.com/], was officially released on November 20, 2025. The global media exhibition period will run from November 21 to December 20, 2025. This British international art competition received submissions from artists across dozens of major countries and regions worldwide. After review by Gallery NAT's…
More Releases for HER2
HER2-Positive Breast Cancer (HER2+ BC) Clinical Market to Reach USD 21.46 Billio …
Sub-Headline: The global HER2-Positive Breast Cancer Clinical Market is expected to rise from USD 13.82 billion in 2023 to USD 21.46 billion by 2030, registering a CAGR of 6.5%, driven by rapid uptake of antibody-drug conjugates (ADCs), dual-targeted therapies, and AI-enabled precision oncology diagnostics.
Introduction
The HER2-Positive Breast Cancer (HER2+ BC) Clinical Market is undergoing a major transformation fueled by next-generation targeted therapies, breakthrough ADCs, biosimilar expansion, and genomic testing advancements. HER2+…
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
